Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra for fever and mucositis during neutropenia in autologous SCT for multiple myeloma
2016-004419-11Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of anakinra in multiple myeloma (MM), mucositis and febrile neutropenia (FN), sponsored by Radboud University Medical Center. Primary endpoint: Safety and maximum tolerated dose of anakinra. Started Dec 2016; status: completed.
02
Drugs
anakinra
03
Conditions
multiple myeloma (MM)mucositisfebrile neutropenia (FN)
Beyond the preview
Go deeper on 2016-004419-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004419-11.